LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

LLY

718.97

-2.33%↓

JNJ

152.31

-1.21%↓

ABBV

181.63

-0.89%↓

NVO

67.98

-2.07%↓

UNH

302.1

-1.61%↓

Durect Corp

Отворен

0.55 -5.17

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.55

Максимум

0.58

Ключови измерители

By Trading Economics

Служители

21

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+747.46% upside

Дивиденти

By Dow Jones

Следващи печалби

12.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-731K

19M

Предишно отваряне

5.72

Предишно затваряне

0.55

Durect Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2025 г., 23:25 ч. UTC

Горещи акции

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21.05.2025 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21.05.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefónica's Operations in Uruguay

21.05.2025 г., 21:01 ч. UTC

Значими двигатели на пазара

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21.05.2025 г., 23:49 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21.05.2025 г., 23:37 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21.05.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21.05.2025 г., 23:32 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21.05.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21.05.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21.05.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21.05.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21.05.2025 г., 23:28 ч. UTC

Печалби

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21.05.2025 г., 23:27 ч. UTC

Печалби

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21.05.2025 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21.05.2025 г., 23:22 ч. UTC

Топ новини

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21.05.2025 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21.05.2025 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21.05.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21.05.2025 г., 23:04 ч. UTC

Топ новини

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21.05.2025 г., 21:46 ч. UTC

Топ новини

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21.05.2025 г., 21:42 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21.05.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefónica's Ops in Uruguay

21.05.2025 г., 21:07 ч. UTC

Топ новини

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21.05.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Durect Corp Прогноза

Ценова цел

By TipRanks

747.46% нагоре

12-месечна прогноза

Среден 5 USD  747.46%

Висок 5 USD

Нисък 5 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Durect Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

2

Купи

1

Задържане

0

Продай

Финанси

$

Относно Durect Corp

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.